Lantern Pharma Inc. (Nasdaq: LTRN) announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows.
The expansion broadens access to advanced computational tools, allowing researchers to evaluate molecular candidates more efficiently. By integrating with Lantern’s proprietary AI platform, the LQM aims to accelerate the identification of promising drug candidates, potentially reducing development timelines and costs. This development is significant for the pharmaceutical industry, where computational approaches are increasingly critical in early-stage drug discovery.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI and machine learning through its proprietary RADR platform to transform cancer therapy development. Its clinical pipeline includes LP-184, LP-284, and LP-300, with LP-300 being evaluated in the HARMONIC Phase 2 trial. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The company’s withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform, representing a new revenue stream. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
For more information, visit the company’s newsroom at https://ibn.fm/LTRN.
